Kim Byung-Jang – CEO, Mega Medical – South Korea
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
Since its establishment in 1995, Mega medical Co., Ltd. has localized medical equipment for ear-note-and throat (ENT), and currently been ranked No. 1 in domestic market share. This company will make every effort not only to maintain No. 1 market share in domestic market but also to take the first position in overseas markets.
1997 Specialized ENT unit launch
1999 Patent acquisition for wall-type nebulizer
2005 Cell-Q, a new obesity treatment product development
2006 Wireless visual system is selected as (wireless visual system) the world best quality product
2007 Digital wireless visual system development
2008 Obesity treatment device solution, Nato irrigation development
2009 HD visual system Development
2010 technical development for ENT Microscope development
2011 LIPO carbon therapy development
2013 Obesity treatment complex device development
Through consistent overseas market development since the establishment, Mega medical Co., Ltd. have exported out products over 40 countries including Europe, Asia, China, and Middle-East, and worked for global network construction.
Contact Details
Domestic inquiries
domestic@megamedical.co.kr
Tel. 1588-4493 (02-3662-4493)
Fax. 02-3661-0120
For overseas clients
Inquiry about products and warranty
webmaster@megamedical.co.kr
Tel. +82-2-3662-4493
Fax. +82-2-3661-0120
Address
#2504, 2505, A Bldg, Woolim blue 9 Business Center, 583, Yangcheon-ro, Gangseo-gu, Seoul (ZIP 157-779)
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
See our Cookie Privacy Policy Here
